A platform for personalized cancer treatment options
xCures/CancerCommons Enhanced Learning Treatment Selection and Analysis With Outcomes Research (XCELSIOR) Study: A Patient-Centric Platform Trial for Precision Oncology
xCures · NCT03793088
This study is testing a new way to create personalized cancer treatment plans for people with advanced cancers like glioblastoma and pancreatic adenocarcinoma by using expert advice and technology to review their medical information.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 0 Years and up |
| Sex | All |
| Sponsor | xCures (industry) |
| Locations | 1 site (Los Altos, California) |
| Trial ID | NCT03793088 on ClinicalTrials.gov |
What this trial studies
XCELSIOR is a non-interventional data registry focused on collecting and analyzing information about cancer treatments, decisions, and patient outcomes. It operates through a virtual tumor board that reviews patient data and generates personalized treatment options based on expert judgment and artificial intelligence. Patients enroll via the Cancer Commons Web portal, consenting to have their medical information reviewed and tracked for safety and efficacy outcomes. This observational study aims to improve treatment strategies for patients with advanced cancers like glioblastoma and pancreatic adenocarcinoma.
Who should consider this trial
Good fit: Ideal candidates include both male and female patients with known or suspected advanced or recalcitrant cancers.
Not a fit: Patients who are not residents of the United States or its territories will not benefit from this study.
Why it matters
Potential benefit: If successful, this platform could provide tailored treatment options and improve outcomes for patients with advanced cancer.
How similar studies have performed: Other studies utilizing patient-centric registries and virtual tumor boards have shown promise in improving treatment outcomes, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Both male and female patients with known or suspected recalcitrant or advanced cancer are eligible to enroll through the Cancer Commons Website * Patients with any performance status, comorbidity or disease severity are eligible * Patients or their legally-authorized representative must be willing and able to provide written, informed consent (and assent, if applicable) Exclusion Criteria: * Patients must be a resident of or receiving care within the United States or US territories.
Where this trial is running
Los Altos, California
- Cancer Commons — Los Altos, California, United States (RECRUITING)
Study contacts
- Principal investigator: Mark Shapiro — xCures / Cancer Commons
- Study coordinator: Bryan J Federowicz
- Email: bfederowicz@xcures.com
- Phone: 707-641-4475
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Oncology, Glioblastoma, Glioma, Pancreatic Adenocarcinoma